CTSD and proximal spinal muscular atrophy: Schorling and colleagues found that Cathepsin D (CTSD), a lysosomal protease involved in protein degradation in skeletal and heart muscles, was upregulated at baseline in SMA patients compared to controls, and decreased more markedly after nusinersen treatment in the responder group compared to non-responders [42].